| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate |
1998-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d44b3e0cee48baf41c91e4d52a77b14 |
| publicationDate |
2005-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
SK-284779-B6 |
| titleOfInvention |
Quinolines and quinazolines, processes for their preparation, intermediates for their preparation, their use and pharmaceutical compositions based thereon |
| abstract |
Quinolines and quinazilines of formula (I) wherein R 1 is C 1 -C 4 alkoxy optionally substituted by one or more fluorine atoms; R 2 is hydrogen or C 1 -C 6 alkoxy optionally substituted by one or more fluorine atoms; R 3 represents a five- or six-membered heterocyclic ring which is optionally substituted; R 4 represents a four-, five-, six- or seven-membered heterocyclic ring which is optionally fused to a benzene ring or a five- or six-membered heterocyclic ring, such ring system being optionally substituted as a whole; X is CH or nitrogen; and L is absent or represents a cyclic group of formula (Ia) or a chain of formula (Ib); and pharmaceutically acceptable salts thereof, which are useful in the treatment, in particular in the treatment of benign prostatic hyperplasia. A process and intermediates for the preparation of these compounds; pharmaceutical compositions based thereon and their use. |
| priorityDate |
1997-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |